<DOC>
	<DOCNO>NCT02269488</DOCNO>
	<brief_summary>This open-label , single arm , multicenter study enroll approximately 100 subject . The study design gather safety tolerability data Japanese child 2 6 year age would support approval MEDI3250 Japan .</brief_summary>
	<brief_title>A Phase 3 Open-label Study Evaluate Safety MEDI3250 Healthy Japanese Children Age 2 Years Through 6 Years</brief_title>
	<detailed_description>For child age 2 year 6 year , recommend dosage schedule intranasal administration 0.2 mL ( 0.1 mL per nostril ) . For child previously vaccinate seasonal influenza , second dose give interval least 4 week . For safety tolerability endpoint , data gather solicited symptom , AEs SAEs .</detailed_description>
	<criteria>1 . Healthy medical history physical examination OR presence stable underlie chronic medical condition hospitalization require previous year . 2 . Age 2 6 year age time administration . 3 . A write informed consent obtain subject 's legally acceptable representative . 4 . Ability parent/guardian understand comply requirement protocol． 5 . Parent/guardian available telephone email． 1 . Previous administration present study 2 . Participation another clinical study investigational product last 3 month 3 . Acute illness evidence significant active infection time investigational product administration 4 . Fever ≥99.5°F ( 37.5°C ) time investigational product administration 5 . Any drug therapy 15 day prior randomization expect drug therapy 28 day post last dose exception follow classes/types medication , allow : Topical corticosteroid , calcineurin inhibitor , antifungal uncomplicated dermatitis ; Chronic medication ( include take asneeded basis ) well tolerate initiate and/or dosage change within 90 day prior randomization . 6 . Current expect receipt immunosuppressive medication within 28day window around dose , include immunosuppressive dose corticosteroid , define ≥20 mg/day prednisone equivalent , give daily alternate day ≥15 day ( intranasal , intraarticular , topical corticosteroid permit ) ; Note : topical corticosteroid uncomplicated dermatitis may use throughout study accord judgment investigator ; topical calcineurin inhibitor may use accordance package insert entry study participation . 7 . Any known immunosuppressive condition immune deficiency disease include know suspected infection human immunodeficiency virus ( HIV ) ; 8 . History allergic disease reaction likely exacerbate component investigational product include allergy egg , egg protein , gentamicin , gelatin serious , life threatening , severe reaction previous influenza vaccination ; 9 . Use aspirin salicylatecontaining medication within 28 day prior enrolment expect receipt 28 day final vaccination ; 10 . History GuillainBarré syndrome ; 11 . Use antiviral agent activity influenza virus ( include amantadine , rimantadine , oseltamivir , zanamivir ) within 28 day prior first dose investigational product anticipate use agent within 28 day last scheduled vaccination ; 12 . Administration live virus vaccine within 30 day prior enrolment , receipt another live virus vaccine expect within 30 day study vaccination ; 13 . Administration inactivate vaccine within 14 day prior enrolment receipt another inactivate vaccine expect within 14 day study vaccination ; 14 . Receipt blood product within 90 day prior vaccination expect receipt study ; 15 . Involvement plan conduct study ( applies AstraZeneca staff staff study site parent/guardian ) 16 . Any condition , opinion investigator , might interfere interpretation evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>MEDI3250</keyword>
	<keyword>Japanese child</keyword>
</DOC>